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Abstract
Tracer experiments in rats mimicking type II primary hyperoxaluria, with an expanded intracellular pool of hydroxypyru-
vate, showed that the excess formation of oxalate did not originate from its immediate precursor glyoxylate. In these
animals, the hepatic and kidney activities of oxalate synthesising enzymes such as lactate dehydrogenase and glycolate
oxidase were normal, but tissue lipid peroxidation was significantly higher. In vitro experiments established that in a mild
alkaline solution, hydroxypyruvate underwent auto-oxidation to form oxalate and H O and also inhibited lactate2 2
dehydrogenase and glycolate oxidase from oxidising glyoxylate to oxalate. On the basis of the experimental evidence, we
suggest that in type II primary hyperoxaluria, the accumulating hydroxypyruvate could reduce the intracellular pool of
glyoxylate and on ageing, give rise to excess oxalate and H O , to cause oxalosis in the former and free radical2 2
mediated-cell injuries in the latter. q 1997 Elsevier Science B.V.
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 .Type II primary hyperoxaluria PH II , a genetic
disorder of serine metabolism in man, manifests due
to the absence of the enzyme D-glycerate dehydroge-
 .  . w xnase D-GD that acts on hydroxypyruvate HP 1,2 .
Clinically, the disease is characterised by an abnor-
mally high urinary excretion of L-glycerate and ox-
alate, the latter leading to the manifestation of cal-
cium oxalate nephrolithiasis, nephrocalcinosis and fi-
w xnally to renal failure 1–3 . Conflicting reports have
appeared on the specific nature of the metabolic
events that lead to the development of oxalosis in PH
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II. Oxalosis is suggested to develop due to a
favourable shift in NAD:NADH ratio, caused by the
enzymatic reduction of accumulating HP to L-
 .glycerate by lactate dehydrogenase LDH and this
shift in turn is speculated to induce LDH to act
favourably on glyoxylate and convert it into oxalate
w x2 . On the other hand, the deficiency of glyoxylate
 .reductase GR activity associated with D-GD itself
is suggested as the actual causative factor for the
accumulation of glyoxylate and hence oxalosis in PH
w xII 3–5 . In the present study, the body pool of HP
was made to expand in rats by implanting osmotic
pumps releasing HP and the consequent pathogenic
reactions leading to manifestation of oxalosis and
renal injury have been investigated.
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Male Wistar rats weighing f250 g were fasted for
24 h prior to surgical treatment, but had access to
water. Laparotomy was performed under mild ether
anaesthesia, by making a 1.5 cm dorsal incision. Alzet
 .osmotic pump model: 2002 , primed to deliver HP
fixed release rate: 0.5 mlrh, reservoir volume:
200 m l, concentration of test chemical, HP:
.2 mmolrml , for a period of two weeks, was inserted
into the peritoneal cavity and the incision sutured, as
w xoutlined earlier 6 . Alzet osmotic pump delivers
predictable levels of the test chemical through contin-
uos outflow and ensures that the chemical is present
for a sufficient duration to allow its effect to develop.
For 24 h collection of urine samples, the treated
animals were individually housed in Metrap animal
restraining and metabolic cages, having special provi-
sion for collection of urine without contamination by
faecal matter. Aliquots of acidified urine samples
were pre-treated with activated charcoal to eliminate
the interference of ascorbate in the oxalate assay.
Urinary oxalate was determined colorimetrically by
following the procedures, developed in our laboratory
using a combined preparation of the enzymes, banana
w xoxalate oxidase and horseradish peroxidase 7 . Ox-
alate oxidase, needed for the assay, was isolated and
purified from the peels of fully ripened banana fruits
 .Musa paradisiaca c.v. French plantain in our labora-
w xtory, as described earlier 7 . Such enzyme prepara-
tions, obtained from banana fruit peel, had a specific
activity of about 4 Urmg protein, an unit being the
amount of enzyme needed to convert 1 mmol of
substrate into product at 378C in 1 min. Horseradish
peroxidase, needed as a coupling enzyme for oxalate
assay, was obtained from Sigma type II, Act,
.200 Urmg solid . For determining the tissue content
of oxalate, aliquots of supernatant, obtained from
 .10% liverrkidney homogenate 20,000=g were
used.
 .LDH and glycolate oxidase GO were purified
from rat liver following the procedures discribed by
w x w14 xFry and Richardson 8 . The amount of C oxalate,
wformed by the action of LDH or GO on 1-
14 xC glyoxylate was determined using banana oxalate
oxidase. The radioactive CO liberated from2
w14 xC oxalate by the action of oxalate oxidase was
trapped in NaOH solution and measured in a liquid
w x w14 xscintillation counter 6 . To determine the C glyco-
late, advantage was taken of the observation that
ascorbic acid selectively decarboxylates glyoxylate
 .but not glycolate or oxalate at pH 7.4 see below .
w14 xC glyoxylate was first decarboxylated by adding
20mmol of ascorbic acid and the trapped 14CO was2
determined. Radioactive oxalate was separately esti-
w x w14 xmated 6 . The amount of C glycolate was com-
puted by calculating the differences between the total
w14 xradioactivity and that of C glyoxylate and
w14 xC oxalate. Tissue lipid peroxidation was assayed
by estimating the amount of malonaldehyde formed
w x9 .
LDH catalyses the coupled oxidation of glyoxylate
w xto oxalate and its reduction to glycolate 2,10 . It also
brings about the reversible reduction of HP to L-
glycerate. These two reactions were combined and
w 14 xthe effect of HP on the oxidation of 1- C glyoxylate
by a purified preparation of rat liver LDH at pH 7.4
was examined. HP, at equimolar concentration or
higher than that of glyoxylate, inhibited the oxidation
of glyoxylate to oxalate, brought about by LDH with
 .NADH or NAD as cofactor Table 1 . A similar
inhibitory effect of pyruvate on LDH was also ob-
served in the presence of NADHrNAD. These find-
ings are at variance with the reported stimulation of
w xLDH by HP 2 . Glycolate oxidase is yet another
w xenzyme that involved in the synthesis of oxalate 10 .
Addition of HP to a purified preparation of rat liver
w14 xGO reduced formation of C oxalate from radioac-
tive glyoxylate and the extent of inhibition depended
 .on the concentration of HP Table 1 .
In vitro experiments showed that HP, in a mild
alkaline solution, gave rise to oxalate and H O , by2 2
undergoing auto-oxidation. The fresh oxalate formed
in such a solution could be detected 24 h post-incuba-
 .tion room temperature using oxalate oxidase. The
amount of oxalate formed depended on the concentra-
tion of HP, period of incubation, the pH, the tempera-
ture of the solution and the concentration as well as
 .the type of metal ions added Table 2 . The addition
of catalase to such a solution prevented the formation
of oxalate thereby confirming both the generation of
H O during autooxidation of HP as well as its2 2
involvement in the production of the final product,
viz. oxalate. HP if allowed to remain for 48-72 h
either in rat blood or liver homogenate at pH 7.4 at
 .room temperature, also gave rise to oxalate Table 2 .
HP, when added to a solution of glyoxylate, decar-
boxylated glyoxylate. The direct addition of H O or2 2
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Table 1
w 14 x w14 xEffect of HP and pyruvate on rat liver LDH and GO catalysing the oxidation of 1- C glyoxylate to C oxalate
14 14w x w xEnzyme Cofactor mmol HP mmol C glycolate C oxalate
formed nmol formed nmol
 .LDH pH 7.4 NADH
0.5 y 1050 68
0.5 5.0 490 27
0.5 10 210 13
NAD
5 y 680 220
5 5.0 445 122
5 10 170 41
NADH Pyruvate
0.5 y 1011 71
0.5 10 342 32
NAD
5 y 598 204
5 10 237 56
 .GO pH 7.4 y y y 96
y 5 y 61
y 15 y 24
w 14 xLDH assay system consisted of 21 mg of enzyme protein, 5 mmol of 1- C glyoxylate and other reagents as indicated. GO assay system
w 14 xconsisted of 32 mg of enzyme protein and 7 mmol of 1- C glyoxylate. The reaction was carried out at 378C for 1 h.
w 14 xascorbic acid to 1- C glyoxylate also caused similar
decarboxylation. Addition of catalase to the mixture
prevented the decarboxylation indicating a possible
role for the HP-generated H O in decarboxylation2 2
 .data not presented .
The possibility that the ageing of HP can also give
rise to oxalate in vivo was examined by employing
animal models mimicking the symptoms of L-glyceric
aciduria. Urine samples obtained from animals im-
planted with Alzet osmotic pumps releasing HP at a
 .steady rate were assayed for oxalate Table 3 . Rats
implanted with HP-pump excreted higher amount of
urinary oxalate post-implantation, compared with
pre-implantation. Similarly, the oxalate content in
liver and kidneys of these animals showed an in-
crease on fourteenth day of post-implantation. How-
Table 2
New formation of oxalate in buffer solution, rat blood sample and liver homogenate after incubation with HP
Sample HP mmol Newly formed oxalate nmol
24 h 48 h 72 h
Buffer pH 7.4 5 7 13 27
Buffer pH 7.4 10 8 29 41
qqBuffer pH 7.4q Cu 10 41 95 140
qqBuffer pH 7.4q Mg 10 122 220 640
qqBuffer pH 7.4q Mn 10 146 261 712
Buffer pH 7.4q Catalase 10 y y y
0 .Buffer pH 7.4 45 C 10 78 130 260
Buffer pH 8.8 10 27 64 111
Blood 10 3 8 17
Liver homogenate 10 9 17 29
Except where indicated, reaction was carried out at room temperature. Oxalate was detected and measured using banana oxalate oxidase
w x7 .
( )K.G. Ragha˝an et al.rBiochimica et Biophysica Acta 1362 1997 97–102100
Table 3
Urinary excretion and tissue levels of oxalate, activities of oxalate synthesising enzymes and the level of lipid peroxidation in rats
implanted HP-pump
Sample MetaboliterEnzymer Control Pre-implantation Post-implantation
LPO Dayy1 Day 7 Day 14
Urine
Oxalate 0.75"0.13 2.58"0.49 4.60"0.49
Liver
Oxalate 1.04"0.20 1.52"0.22 2.02"0.59
LDH 0.69"0.02 0.65"0.05 0.70"0.03
GO 1.17"0.12 0.98"0.06 1.00"0.17
LPO 6.38"0.54 10.24"1.71 13.55"0.59
Kidney
Oxalate 0.36"0.05 3.04"0.76 5.03"0.66
LDH 0.52"0.04 0.52"0.04 5.54"0.19
GO 0.28"0.04 0.27"0.02 0.28"0.23
LPO 5.61"0.34 13.08"4.00 13.16"1.82
Per cent radioactivity recovered as 9.30"1.27 7.63"1.27 7.89"0.93
14w xC oxalate from administered
14w x1- C glyoxylate
Urinary oxalate: mgr24 h; tissue content of oxalate: mgrg wet wt., 10% tissue homogenate was used for determining the content of
metabolites, the activities of enzymes and the level of lipid peroxidation LDH: Urmg protein; GO: nmol glyoxylate oxidisedrmg
 . w14 xproteinr30 min. LPO: nmol thiobarbituric acid reactive substances TBARS rmg proteinr30 min. C oxalate recovered: percent
radioactivity recovered in the urinary oxalate from the administered radioactive glyoxylate.
ever, the activities of oxalate synthesising enzymes
such as LDH and GO in these tissues remained
 . w14 xunaltered Table 3 . The injection of C glyoxylate
to animals receiving HP did not lead to enhanced
w14 x w14 xoxidation of C glyoxylate to C oxalate compared
w14 x  .with rats receiving only C glyoxylate Table 3 .
These results indicate that in the presence of excess
HP, LDH and GO are not involved in the increased
oxidation of glyoxylate to oxalate and the excess
oxalate may have originated from a precursor other
than glyoxylate.
The histopathological examination of the kidney
tissues showed extensive tubular necrosis and the
deposition of oxalate crystals in tubules on the four-
teenth day following HP administration data not
.presented and during this period, the levels of lipid
peroxidation in liver and kidneys also showed marked
 .elevation Table 3 . These results indicated that HP
could be a direct source of oxalate as well as a
causative factor for membrane damage via H O -2 2
mediated free radicals. In addition, the presence of
metal ions such as Fe, Mg and Mn, as pointed out
earlier, could accelerate the oxidation of HP and
hence the production of H O . Therefore, the Fenton2 2
reaction-mediated free radical generation and the
consequent membrane damage could take place under
w xsuch conditions 11 . Recent evidence indicates that
an oxygen andror hydroxyl radical reaction mecha-
nism can injure renal tubular cells and promote cal-
cium oxalate crystallisation within the cells. Oxalate
itself or in combination with FeSO has been re-4
ported to enhance malonaldehyde formation, and also
induce lipid peroxidation through inhibition of cata-
lase. Administration of sodium oxalate to animals
leads to elevated level of lipid peroxidation in both
liver and kidney, increased SOD activity in liver and
decreased catalase activity in both liver and kidney
w x12–18 . Thus, kidney damage due to H O -linked2 2
free radicals seems to be an additional factor in-
volved in the manifestation of PH II.
On the basis of the experimental evidence obtained
in the present study, in type II hyperoxaluria, the
elimination of HP at the initial phase of the disease
can be presumed to proceed by its metabolic conver-
 .sion to L-glycerate by LDH Fig. 1 . Along with other
substrates like pyruvate and lactate, the ever increas-
ing concentration of HP can easily saturate LDH and
minimise its interaction with glyoxylate. Under such
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Fig. 1. Proposed mechanism for the manifestation of oxalosis and renal necrosis in PH II.
conditions, the unmetabolised HP could build up in
the body leading to its deposition over a prolonged
period in the tissues. At the conducive physiological
pH of 7.4, the ageing HP could undergo auto-oxida-
tion, giving rise to oxalate and H O formation2 2
non-enzymatically. This would explain the genesis of
L-glyceric aciduria and oxalosis. The oxidative stress
associated with the metabolic formation of H O2 2
from HP could in turn lead to plasma membrane
damages. Once membrane damage is inflicted, the
subsequent handling of oxalate by cells would be-
come difficult and as a result oxalate may start
adhering to damaged cells and precipitate. The mas-
sive deposition of oxalate in renal tissues under such
a condition eventually would lead to renal injury.
This mechanism is consistent with the manifestation
of L-glyceric aciduria and oxalosis as well as renal
 .necrosis Fig. 1 .
The hypothesis relating to a shift in NADrNADH,
favouring LDH to act on glyoxylate, though could
explain both glyceric aciduria and oxalosis, appears
inconsonant. Whether HP gets reduced to D-glyceric
acid by D-GD as in normal individuals or to L-glyceric
acid by LDH as in L-glyceric aciduria patients, the
amount of NAD produced would be the same in both
the cases. Since NAD and NADH are common cofac-
tors for several enzymes, it is difficult to visualise a
selective role for NAD in inducing LDH to act on
glyoxylate. Besides, unless glyoxylate is made avail-
able in excess for LDH to act, the enhanced forma-
tion of oxalate cannot be explained under such condi-
tions.
D-GD is reported to possess GR activity and a
recent report confirms deficiency of both enzyme
w xactivities in the liver of a PH II patient 4 . The close
correlation between the activities of these enzymes is
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suggested to be compatible with the idea that they are
w xidentical gene products 5 . Therefore, it is suggested
that the failure to metabolise cytosolic glyoxylate to
glycolate, caused by the simultaneous deficiency of
GR, would result in the increased oxidation of glyox-
ylate to oxalate, possibly by the action of LDH.
However, this suggestion fails to explain the forma-
tion of L-glyceric acid from HP which accumulates
due to deficiency of D-GD. The major pathway of
glyoxylate metabolism in the human liver is through
transamination to glycine by the peroxisomal enzyme
alanine:glyoxylate aminotransferase and its impor-
tance is emphasised by the manifestation of primary
hyperoxaluria type I as well as pyridoxine deficient
hyperoxaluria syndrome. If glyoxylate should accu-
mulate due to the deficiency of GR, it could be
expected to undergo transamination to excess glycine
and the excess presence of both, the precursor and the
product, could be detected in the urine of PH II
patients. But no such finding has been reported so
far.
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